#Scinai Immunotherapeutics #Israel #Jerusalem #$4 Million Financing #NASDAQ SCNI

Scinai Immunotherapeutics Secures $4 Million in Financing

Scinai Immunotherapeutics Ltd., which trades on NASDAQ under the symbol SCNI, has recently announced the successful closing of a financing deal totaling $4.0 million. This financing was achieved through a private placement of 2,458,334 American Depositary Shares (ADSs), alongside warrant inducement efforts. Each ADS corresponds to 40,000 ordinary shares, and the private placement also involved Series A-1 Warrants that enable the purchase of an additional 3,687,501 ADSs.

Furthermore, Scinai reported that it conducted an immediate exercise of existing warrants, allowing for the purchase of up to 879,194 ADSs at a reduced exercise price of $1.20 per ADS. New warrants have also been issued, allowing further purchases of up to 1,318,791 ADSs. This strategic financing initiative is aimed at bolstering the company's financial resources to enable them to advance their existing client programs, pursue new contract development and manufacturing organization (CDMO) opportunities, and make further investments in their immunotherapy initiatives.

CEO Amir Reichman expressed optimism regarding this financing, stating, “Completing this financing, alongside our recently announced CDMO agreement, strengthens our ability to execute customer programs, develop our CDMO platform, and selectively advance our immunotherapy pipeline.” He emphasized that the recent CDMO agreement outlines a phased approach for an integrated program and highlights the commitment expected under these future phases.

Scinai projects that their current operating plan, alongside existing cash resources and proceeds from this financing, positions them for operational continuity until late 2027. They believe that successfully activating the later phases of their agreements could potentially extend their operational runway into 2028, depending on several factors, including sales achievements, timely client payments, and successful contract execution.

Notably, the company acknowledges the need for additional financings to pursue their strategic ambitions or to adapt to any evolving business necessities. The gross proceeds from the private placement and warrant inducement transaction have been calculated at approximately $4.0 million, prior to deducting expenses and fees related to the placement agent.

A.G.P. / Alliance Global Partners acted as the sole placement agent in these financial transactions, which positions Scinai for strategic growth while maintaining a focus on its innovative immunotherapeutic developments.

These ADSs resulting from this issuance have been duly registered for resale under the company's effective registration statement. However, it is important to note that both the private placement and the new warrants issued aren't registered under U.S. or state securities laws, marking them under specific regulatory exemptions.

For investors considering participation, it's essential to be informed that these securities cannot be sold in the U.S. unless they are registered or fall under applicable exemptions, as stipulated in securities regulations. Scinai plans to register these newly issued securities with the SEC to enable their resale.

The financing marks a significant step forward for Scinai Immnotherapeutics as it pushes ahead to solidify its position in biopharmaceutical development and enhance its immune-focused therapeutic offerings. For more insights about Scinai and their future endeavors, visit their official website at www.scinai.com.